ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,294.90
0.05%
Brent Oil
83.215
0.11%
Bitcoin
64,411.79
0.64%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) News

Sanofi (SNY)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNY
DateTimeSourceHeadlineSymbolCompany
25/04/202412:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:SNYSanofi
19/04/202412:31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNASDAQ:SNYSanofi
23/02/202419:02Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
23/02/202416:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
15/02/202417:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
14/02/202420:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNYSanofi
25/01/202419:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:SNYSanofi
23/01/202412:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
23/01/202411:05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:SNYSanofi
23/01/202410:40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:SNYSanofi
23/01/202406:00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:SNYSanofi
17/01/202418:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
09/01/202407:14Dow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitNASDAQ:SNYSanofi
27/12/202316:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
21/12/202307:25Dow Jones NewsSanofi Ends Drug Program After Late-Stage Trial in Lung Cancer FailsNASDAQ:SNYSanofi
19/12/202312:28Dow Jones NewsInnate Pharma Shares Rise after Sanofi Exercises Licensing OptionNASDAQ:SNYSanofi
12/12/202310:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:SNYSanofi
11/12/202322:18Dow Jones NewsSanofi Terminates Agreement with Maze Therapeutics Following FTC OppositionNASDAQ:SNYSanofi
11/12/202306:50Dow Jones NewsSanofi Sees Improvement in Trial Results of Cancer Drug SarclisaNASDAQ:SNYSanofi
07/12/202307:34Dow Jones NewsSanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage TrialNASDAQ:SNYSanofi
07/12/202307:20Dow Jones NewsSanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030NASDAQ:SNYSanofi
06/12/202313:20Dow Jones NewsTrending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage TrialsNASDAQ:SNYSanofi
06/12/202310:14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNASDAQ:SNYSanofi
30/11/202314:23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNASDAQ:SNYSanofi
30/11/202313:30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNASDAQ:SNYSanofi
27/11/202315:31Dow Jones NewsTrending: Sanofi's Notus Trial Meets Primary EndpointNASDAQ:SNYSanofi
27/11/202307:40Dow Jones NewsSanofi Says Notus Phase 3 Trial of Dupixent Met Primary EndpointNASDAQ:SNYSanofi
27/11/202306:30GlobeNewswire Inc.Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNASDAQ:SNYSanofi
07/11/202321:01AllPennyStocks.comOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That TimeNASDAQ:SNYSanofi
07/11/202313:56Dow Jones NewsSanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source SaysNASDAQ:SNYSanofi
 Showing the most relevant articles for your search:NASDAQ:SNY

Your Recent History

LSE
BIRD
Blackbird
LSE
JSE
Jadestone Energy
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved